Less than a tenth of individuals eligible to benefit from weight-loss injections like Wegovy can access them, states the World Health Organization as it releases its first recommendations on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just availability to GLP-1 medication.
Per forecasts, more than two billion will be living with obesity by 2030 without intervention.
"The latest guidelines acknowledges that obesity is a chronic disease that can be addressed with comprehensive and continuous support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and distribution challenges are key barriers to universal availability to the jabs that can aid individuals in losing substantial body mass, explains the organization.
GLP-1 Therapy Scarcity
Even under the current best projected scenario, the supply of these medications might only reach approximately 100 million people – under 10% of eligible patients, as stated by the WHO.
The guideline urges nations and manufacturers to widen availability, by strategies such as patent sharing.
The intellectual property rights on semaglutide – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in multiple countries in 2026.
The Way Obesity Drugs Function
GLP-1 drugs imitate a body's own hormone to delay gastric emptying, suppress the appetite and boost the sense of being full so individuals consume fewer calories.
Patients typically start to lose weight within a few weeks of starting on the weekly injections.
Studies suggests people may see weight return a year later of stopping the medication, because their usual appetite return.
To be overweight or obese elevates your likelihood for experiencing medical conditions, such as diabetes, cardiovascular issues, stroke, and certain cancers.
Excess weight concerns individuals in all nations and was linked to over three and a half million fatalities worldwide in 2024, as per the WHO.
